Compare Amphastar Pharmaceuticals Inc (AMPH) vs CSX Corporation (CSX) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

CSX trades at $49.41, slightly above the consensus price target of $48.21, with a 0.12% daily gain. The technical outlook is bullish based on moving averages, though RSI levels suggest overbought conditions. Recent earnings have shown mixed results, beating estimates in Q1 2026 but missing in Q4 2025, while revenue has declined from $14.9B in 2022 to $14.1B in 2025. The company maintains strong profitability with a 21.55% net income margin and recently announced a $0.14 dividend payable in June 2026.

The stock faces headwinds from declining revenue and high valuation multiples (P/E of 30.31), but analyst sentiment remains positive with 56.52% buy ratings. Key risks include freight demand volatility and elevated debt levels. Upside potential exists if operational improvements and margin expansion initiatives succeed, but investors should weigh rich valuations against growth prospects.